Cipla announced its highest-ever quarterly revenue of INR 7,589 Cr in Q2 FY26, marking an 8% year-over-year increase. EBITDA stood at INR 1,895 Cr with a margin of 25%. PAT reached INR 1,351 Cr, a 4% increase. Strong performance in India, North America, and One Africa contributed to this robust profitability.
Financial Performance Highlights
Cipla reported a record-breaking quarterly performance in Q2 FY26:
- Revenue: INR 7,589 Cr, up 8% year-over-year
- EBITDA: INR 1,895 Cr, with a margin of 25%
- PAT: INR 1,351 Cr, an increase of 4% year-over-year
Business Segment Performance
Key highlights from different business segments include:
One India
Revenue of INR 3,146 Cr, a 7% increase. Foracort ranked as the #1 brand in the market.
North America
Generated $233 Mn in revenue. Albuterol ranked #1 in the U.S. Albuterol MDI market with a 22% market share.
One Africa
Revenue of $134 Mn, a 5% increase. South Africa’s private sector grew at a market multiple of 1.3x.
Emerging Markets & Europe
Revenue reached $110 Mn, a significant increase of 15%. Highest-ever quarterly revenue was recorded.
Strategic Initiatives and Developments
Cipla is focusing on sustainable progress and enduring impact through several initiatives:
- Delivering strong growth in trade generics and consumer health.
- Strengthening its presence in chronic care with collaborations, including the introduction of Yurpeak (Tirzepatide) in partnership with Eli Lilly for diabetes and weight management.
- Empowering the fight against antimicrobial resistance (AMR) with stewardship programs and innovative therapies, such as Huena and Zemdri.
Consumer Wellness Franchise
The global consumer wellness franchise showed strong performance with key brands maintaining leading positions:
- One India: Consumer brands generated revenue of INR 404 Cr. Top brands include Nicotex, Omnigel, and Cofsils.
- One Africa: Consumer brands in South Africa generated revenue of ZAR 437 Mn. Cipla Actin and Broncol are key brands.
Source: BSE